"The exquisite sensitivity and specificity of our recently developed mAb enables maximum anti-tumor response to our PB-223 ADC with minimal toxicity in the preclinical animal studies. The target is ...

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody ...

ADCs combine antibodies with drug payloads for targeted therapy, but complex manufacturing requires monitoring CQAs across multiple entities.

NAMkind™ models have now been tested against a wide set of marketed ADC molecules, showing close correlation with clinical results in terms of the toxic impact in the liver and side effect profile in ...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced ...

[Reference] Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQᵀᴹ technology (Press ...

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...

PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its plans to ...

Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract ...

The ADC market presents opportunities across cancer types, payloads, targets, products, users, and countries. Significant growth prospects exist in this multi-billion-dollar industry, offering ...

Antibody–drug conjugates (ADCs) are a class of molecules that provide a means of targeted delivery of cytotoxic agents to tumor cells. ADCs are composed of three components: a monoclonal antibody ...